Tetrabenazine | Ro 1-9569 | VMAT2 Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / Tetrabenazine

丁苯那嗪 /Tetrabenazine {[allProObj[0].p_purity_real_show]}

货号：A769041 同义名： Ro 1-9569;NSC 169886

Tetrabenazine is a VMAT-inhibitor used for treatment of hyperkinetic movement disorder.

Tetrabenazine 化学结构
CAS号：58-46-8

Tetrabenazine 3D分子结构
CAS号：58-46-8

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Tetrabenazine 纯度/质量文件产品仅供科研

货号：A769041 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

Tetrabenazine 生物活性

描述

Tetrabenazine (TBZ; Xenazine) is a potent, selective, reversible depletor of monoamines from nerve terminals. TBZ inhibits the vesicular monoamine transporter type 2 which, in humans, is expressed nearly exclusively in the brain. TBZ is rapidly metabolized in the liver by carbonyl reductase to stereoisomers of hydrotetrabenazine, some of which are potent inhibitors of vesicular monoamine transporter type 2^[3]. Tetrabenazine, a monoamine depleter and dopamine receptor blocker, is a VMAT-inhibitor used for treatment of hyperkinetic movement disorder^[4]. Tetrabenazine (TBZ) depletes presynaptic dopamine in the CNS. TBZ is most effective in reducing chorea (including Huntington's disease associated chorea), tic associated with Tourette's syndrome and tardive dyskinesias^[5]. TBZ selectively depletes central monoamines by reversibly binding to the type 2 vesicular monoamine transporter. TBZ, at adjusted dosages of up to 100 mg/day, effectively lessens chorea in ambulatory patients with Huntington disease^[6]. Optimized nanoemulsion formulation of a tetrabenazine was robust and its delivery through nasal route is a viable alternative to other routes of administration for treatment of hyperkinesia associated with Huntington's disease^[7].

Tetrabenazine 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01734733	Parkinson's Disease	Phase 1 Phase 2	Active, not recruiting	April 29, 2019	New Zealand ... 展开 >> Auckland City Hospital Auckland, New Zealand 收起 <<
NCT01910480	Effect of Ketoconazole on the ... 展开 >>PK of NBI-98854 in Healthy Subjects 收起 <<	Phase 1	Completed	-	United States, Arizona ... 展开 >> Celerion Tempe, Arizona, United States, 85283 收起 <<
NCT02191358	-		Completed	-	United States, California ... 展开 >> Dr. Michael Dao Garden Grove, California, United States, 92844 United States, Colorado Kaiser Permanente Colorado Denver, Colorado, United States, 80011 United States, Kentucky Gill Heart Institute Lexington, Kentucky, United States, 40508 United States, Maryland IRC Clinics Towson, Maryland, United States, 21204 United States, Massachusetts Internal Medicine & Cardiology Associates Fall River, Massachusetts, United States, 02720 Prima CARE Fall River, Massachusetts, United States, 02720 United States, Virginia Carilion Clinic Christiansburg, Virginia, United States, 24073 收起 <<

Tetrabenazine 参考文献

[1]Kenney C, Hunter C, et al. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007 Jan 15;22(2):193-7.

[2]Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb;48(2):358-62.

[3]Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011 Nov;11(11):1509-23

[4]Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999 Aug;156(8):1279-81

[5]Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother. 2009 Dec;10(17):2883-96

[6]Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006 Feb 14;66(3):366-72

[7]Arora A, Kumar S, Ali J, Baboota S. Intranasal delivery of tetrabenazine nanoemulsion via olfactory region for better treatment of hyperkinetic movement associated with Huntington's disease: Pharmacokinetic and brain delivery study. Chem Phys Lipids. 2020 Aug;230:104917

Tetrabenazine 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

3.15mL

0.63mL

0.32mL

15.75mL

3.15mL

1.58mL

31.50mL

6.30mL

3.15mL

Tetrabenazine 技术信息

CAS号	58-46-8
分子式	C₁₉H₂₇NO₃
分子量	317.423

别名	Ro 1-9569;NSC 169886;trade names Nitoman and Xenazin;TBZ;NSC 172187;Xenazine
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,2-8°C

溶解度

DMSO: 35 mg/mL(110.26 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01734733	Parkinson's Disease	Phase 1 Phase 2	Active, not recruiting	April 29, 2019	New Zealand ... 展开 >> Auckland City Hospital Auckland, New Zealand 收起 <<
NCT01910480	Effect of Ketoconazole on the ... 展开 >>PK of NBI-98854 in Healthy Subjects 收起 <<	Phase 1	Completed	-	United States, Arizona ... 展开 >> Celerion Tempe, Arizona, United States, 85283 收起 <<
NCT02191358	-		Completed	-	United States, California ... 展开 >> Dr. Michael Dao Garden Grove, California, United States, 92844 United States, Colorado Kaiser Permanente Colorado Denver, Colorado, United States, 80011 United States, Kentucky Gill Heart Institute Lexington, Kentucky, United States, 40508 United States, Maryland IRC Clinics Towson, Maryland, United States, 21204 United States, Massachusetts Internal Medicine & Cardiology Associates Fall River, Massachusetts, United States, 02720 Prima CARE Fall River, Massachusetts, United States, 02720 United States, Virginia Carilion Clinic Christiansburg, Virginia, United States, 24073 收起 <<
NCT02582736	-		Completed	-	Canada, Ontario ... 展开 >> Women's College Hospital, Women's College Research Institute Toronto, Ontario, Canada, M5G 1N8 收起 <<
NCT01267188	Tardive Dyskinesia	Phase 2	Completed	-	Canada, Ontario ... 展开 >> Toronto, Ontario, Canada, M5T 1R8 收起 <<
NCT01688037	Tardive Dyskinesia	Phase 2	Completed	-	-
NCT01393600	-		Completed	-	-
NCT01733121	Tardive Dyskinesia	Phase 2	Completed	-	United States, California ... 展开 >> Costa Mesa, California, United States, 92626 Fountain Valley, California, United States, 92708 Oceanside, California, United States, 92056 United States, Colorado Englewood, Colorado, United States, 80113 United States, Florida Boca Raton, Florida, United States, 33486 Hialeah, Florida, United States, 33012 Miami, Florida, United States, 33125 United States, Illinois Chicago, Illinois, United States, 60640 United States, Maryland Baltimore, Maryland, United States, 21287 United States, Michigan Farmington Hills, Michigan, United States, 48334 United States, Ohio Beachwood, Ohio, United States, 44122 Middleburg Heights, Ohio, United States, 44130 United States, Pennsylvania Conshohocken, Pennsylvania, United States, 19428 Phoenixville, Pennsylvania, United States, 19460 United States, Texas Bedford, Texas, United States, 76021 DeSoto, Texas, United States, 75115 Houston, Texas, United States, 77008 Houston, Texas, United States, 77030 Irving, Texas, United States, 75062 San Antonio, Texas, United States, 78229 United States, Washington Richland, Washington, United States, 99352 Puerto Rico Caguas, Puerto Rico, 00725 收起 <<
NCT01688037	-		Completed	-	-
NCT01733121	-		Completed	-	-
NCT01916993	Safety, Tolerability, and PK o... 展开 >>f NBI-98854 in Hepatically Impaired Subjects 收起 <<	Phase 1	Completed	-	United States, Colorado ... 展开 >> DaVita Clinical Research Lakewood, Colorado, United States, 80228 United States, Florida Orlando Clinical Research Center Orlando, Florida, United States, 32809 United States, Minnesota Davita Clinical Research Minneapolis, Minnesota, United States, 55404 收起 <<
NCT02256475	Tourette Syndrome	Phase 1	Completed	-	United States, California ... 展开 >> San Diego, California, United States United States, Florida Kissimmee, Florida, United States St. Petersburg, Florida, United States United States, Illinois Naperville, Illinois, United States United States, Missouri St. Louis, Missouri, United States United States, Nebraska Lincoln, Nebraska, United States United States, New York New York, New York, United States Rochester, New York, United States United States, Virginia Petersburg, Virginia, United States United States, Washington Kirkland, Washington, United States 收起 <<
NCT02138864	Carbon Monoxide-induced Parkin... 展开 >>sonism 收起 <<	Phase 3	Unknown	May 2016	Taiwan ... 展开 >> Chang Gung Memorial Hospital Kaohsiung, Taiwan, 886 收起 <<
NCT02274558	Tardive Dyskinesia	Phase 3	Completed	-	-
NCT02274558	-		Completed	-	-
NCT02236754	Healthy Volunteers ... 展开 >> Diabetes Mellitus, Type 1 收起 <<	Early Phase 1	Withdrawn(Could not recruit pa... 展开 >>rticipants) 收起 <<	March 1, 2017	United States, New York ... 展开 >> Naomi Berrie Diabetes Center New York, New York, United States, 10032 收起 <<
NCT01393600	Tardive Dyskinesia	Phase 2	Completed	-	United States, Arkansas ... 展开 >> Woodland International Research Group, Inc Little Rock, Arkansas, United States, 72211 United States, California Synergy Clinical Research National City, California, United States, 91950 UCSD Outpatient Psychiatry San Diego, California, United States, 92103 PCSD - Feighner Research San Diego, California, United States, 92108 United States, Florida San Marcus Research Clinic, Inc. Miami, Florida, United States, 33015 Medical Research Marseilles Miami, Florida, United States, 33155 Scientific Clinical Research, Inc. North Miami, Florida, United States, 33161 United States, Georgia Atlanta Center for Medical Research Atlanta, Georgia, United States, 30308 United States, Missouri St. Louis Clinical Trials Saint Louis, Missouri, United States, 63118 United States, Texas Clinical Trials of Texas, Inc. San Antonio, Texas, United States, 78229 United States, West Virginia CAMC Clinical Trials Center Charleston, West Virginia, United States, 25304 收起 <<
NCT02405091	Tardive Dyskinesia	Phase 3	Completed	-	-
NCT02679079	Tourette Syndrome	Phase 2	Completed	-	-
NCT02736955	Tardive Dyskinesia	Phase 3	Unknown	-	-
NCT02879578	Tourette Syndrome	Phase 2	Completed	-	United States, Arizona ... 展开 >> Sun City, Arizona, United States United States, California San Diego, California, United States United States, Florida Loxahatchee Groves, Florida, United States Saint Petersburg, Florida, United States Tampa, Florida, United States United States, Illinois Naperville, Illinois, United States United States, Nebraska Lincoln, Nebraska, United States United States, New Jersey Summit, New Jersey, United States United States, New York New York, New York, United States United States, Pennsylvania Norristown, Pennsylvania, United States United States, Tennessee Nashville, Tennessee, United States United States, Texas Fort Worth, Texas, United States United States, Washington Spokane, Washington, United States 收起 <<
NCT03444038	Tourette Syndrome	Phase 2	Enrolling by invitation	June 2019	-
NCT02581865	Tourette Syndrome	Phase 2	Completed	-	-
NCT03452943	TOURETTE SYNDROME	Phase 2 Phase 3	Recruiting	August 28, 2019	-
NCT03530293	Tourette Syndrome	Phase 2	Recruiting	February 2020	-
NCT03567291	Tourette Syndrome	Phase 3	Recruiting	May 22, 2021	United States, Alabama ... 展开 >> Teva Investigational Site 046-0104 Recruiting Dothan, Alabama, United States, 36303 United States, California Teva Investigational Site 046-0101 Recruiting Sacramento, California, United States, 95815 United States, Georgia Teva Investigational Site 046-0116 Recruiting Atlanta, Georgia, United States, 30331 United States, New York Teva Investigational Site 046-0102 Recruiting Rochester, New York, United States, 14618 United States, Texas Teva Investigational Site 060-0163 Recruiting Fort Worth, Texas, United States, 76104 Canada Teva Investigational Site 046-0201 Recruiting Ajax, Canada, L1Z0M1 Teva Investigational Site 046-0202 Recruiting Ottawa, Canada, K2G 1W2 收起 <<
NCT03571256	Tourette Syndrome	Phase 3	Recruiting	December 9, 2019	United States, Florida ... 展开 >> Teva Investigational Site 060-0151 Recruiting Orlando, Florida, United States, 32801 Teva Investigational Site 060-0153 Recruiting Orlando, Florida, United States, 32819 United States, Illinois Teva Investigational Site 060-0164 Recruiting Chicago, Illinois, United States, 60634 United States, Indiana Teva Investigational Site 060-0152 Recruiting Indianapolis, Indiana, United States, 46256 United States, Maryland Teva Investigational Site 060-0167 Recruiting Rockville, Maryland, United States, 20852-4219 United States, Michigan Teva Investigational Site 060-0165 Recruiting Ann Arbor, Michigan, United States, 48105 United States, New York Teva Investigational Site 060-0154 Recruiting New York, New York, United States, 10036 United States, South Carolina Teva Investigational Site 060-0169 Recruiting Charleston, South Carolina, United States, 29414-5834 United States, Tennessee Teva Investigational Site 060-0156 Recruiting Nashville, Tennessee, United States, 37232 United States, Texas Teva Investigational Site 060-0163 Recruiting Fort Worth, Texas, United States, 76104 United States, Washington Teva Investigational Site 060-0162 Recruiting Everett, Washington, United States, 98201-4077 Hungary Teva Investigational Site 060-0901 Recruiting Budapest, Hungary, 1021 Teva Investigational Site 060-0902 Recruiting Szeged, Hungary, 6725 收起 <<
NCT03698331	Tardive Dyskinesia (TD)	Phase 4	Recruiting	April 2019	United States, California ... 展开 >> Neurocrine Clinical Site Recruiting Anaheim, California, United States, 92804 Neurocrine Clinical Site Recruiting Glendale, California, United States, 91206 Neurocrine Clinical Site Recruiting Norwalk, California, United States, 90650 Neurocrine Clinical Site Recruiting Oceanside, California, United States, 92054 Neurocrine Clinical Site Recruiting San Bernardino, California, United States, 92108 United States, Florida Neurocrine Clinical Site Recruiting Hialeah, Florida, United States, 33012 Neurocrine Clinical Site Recruiting Hialeah, Florida, United States, 33013 Neurocrine Clinical Site Recruiting Hialeah, Florida, United States, 33018 United States, Hawaii Neurocrine Clinical Site Recruiting Honolulu, Hawaii, United States, 96817 United States, Michigan Neurocrine Clinical Site Recruiting Ann Arbor, Michigan, United States, 48105 United States, Ohio Neurocrine Clinical Site Recruiting Beechwood, Ohio, United States, 44122 United States, Oklahoma Neurocrine Clinical Site Recruiting Oklahoma City, Oklahoma, United States, 73112 United States, Pennsylvania Neurocrine Clinical Site Recruiting Scranton, Pennsylvania, United States, 18503 United States, Texas Neurocrine Clinical Site Recruiting DeSoto, Texas, United States, 75115 Neurocrine Clinical Site Recruiting Irving, Texas, United States, 75062 Puerto Rico Neurocrine Clinical Site Recruiting San Juan, Puerto Rico, 00926 收起 <<
NCT01795859	Chorea	Phase 3	Completed	-	-
NCT02405091	-		Completed	-	-
NCT01897896	Chorea Associated With Hunting... 展开 >>ton Disease 收起 <<	Phase 3	Completed	-	-
NCT01795859	-		Completed	-	-
NCT01451463	-		Completed	-	United States, Ohio ... 展开 >> The Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT01451463	-		Completed	-	-
NCT02844179	Healthy Subjects	Phase 1	Completed	-	United States, Michigan ... 展开 >> University of Michigan hospitals Ann Arbor, Michigan, United States, 48109 收起 <<
NCT00632645	Huntington Disease	Phase 3	Completed	-	France ... 展开 >> CHU Henri Mondor Creteil, France, 94 收起 <<
NCT03732534	Tourette Syndrome	Phase 2	Enrolling by invitation	August 2020	United States, California ... 展开 >> Neurocrine Clinical Site Anaheim, California, United States, 92805 Neurocrine Clinical Site San Diego, California, United States, 92108 United States, Florida Neurocrine Clinical Site Hialeah, Florida, United States, 33013 United States, Illinois Neurocrine Clinical Site Chicago, Illinois, United States, 60634 Neurocrine Clinical Site Naperville, Illinois, United States, 60563 United States, Nebraska Neurocrine Clinical Site Lincoln, Nebraska, United States, 68526 United States, Texas Neurocrine Clinical Site Houston, Texas, United States, 77058 收起 <<
NCT00642057	-		-	-	-
NCT01543321	Tardive Dyskinesia	Phase 3	Completed	-	France ... 展开 >> CHU Amiens Amiens, Picardie, France, 80000 CH Aix en Provence Aix en Provence, France, 13100 CHU Bordeaux Bordeaux, France, 33076 CHU Caen Caen, France, 14033 CHU Clermont-Ferrand Clermont-ferrand, France, 63003 CHRU Lille Lille, France, 59037 CHU Limoges Limoges, France, 87042 CH des Charpennes Lyon, France, 69100 AP-HM Hopital de la Timone Marseille, France, 13385 CHU Montpellier Montpellier, France, 34295 CHU Nantes Nantes, France, 44093 CHU Nice Nice, France, 06002 CHRU de Nimes Nimes, France, 30900 CHU Saint Antoine Paris, France, 75012 CHU Poitiers Poitiers, France, 86021 CHU de Rennes Rennes, France, 35033 CHU Rouen Rouen, France, 76031 CHU Strasbourg Strasbourg, France, 67091 CHU Toulouse Toulouse, France, 31059 收起 <<
NCT01133353	Tourette's Syndrome	Phase 2	Withdrawn	December 2011	-
NCT00219804	Huntington's Disease	Phase 3	Completed	-	-
NCT03696329	Healthy	Phase 1	Completed	-	India ... 展开 >> Accutest Research Laboratories (I) Pvt. Ltd. Navi Mumbai, Maharashtra, India, 400709 收起 <<
NCT03702855	Healthy	Phase 1	Completed	-	India ... 展开 >> Accutest Research Laboratories (I) Pvt. Ltd. Navi Mumbai, Maharashtra, India, 400709 收起 <<
NCT00362804	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Not Applicable	Completed	-	Canada, Ontario ... 展开 >> Centre for Addiction and Mental Health Toronto, Ontario, Canada, M5T 1R8 收起 <<
NCT02509793	Huntington's Disease	Phase 4	Recruiting	July 2019	United States, Texas ... 展开 >> Methodist Neurological Institute Recruiting Houston, Texas, United States, 77030 Contact: William Ondo, MD 713-363-8390 wondo@houstonmethodist.org 收起 <<
NCT01834911	Huntington Disease	Phase 4	Completed	-	United States, New York ... 展开 >> Terence Cardinal Cooke Health Care Center New York, New York, United States, 10029 收起 <<

丁苯那嗪 /Tetrabenazine {[allProObj[0].p_purity_real_show]}

Tetrabenazine 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Tetrabenazine 质控信息

Tetrabenazine 生物活性

Tetrabenazine 临床研究

Tetrabenazine 参考文献

Tetrabenazine 实验方案

Tetrabenazine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

丁苯那嗪 /Tetrabenazine {[allProObj[0].p_purity_real_show]}

Tetrabenazine 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Tetrabenazine 质控信息

Tetrabenazine 生物活性

Tetrabenazine 临床研究

Tetrabenazine 参考文献

Tetrabenazine 实验方案

Tetrabenazine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Tetrabenazine 纯度/质量文件产品仅供科研